MRC study: when to commence treatment in advanced prostate cancer

Kirk, D.

doi:10.1038/sj.pcan.4500207

Cited by 11 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PCa is the most commonly diagnosed cancer amongst men in Europe and the United States and is the second highest cause of cancer-related morbidity worldwide. It has been reported that PCa is predominant in older men above the age of 50 (Kirk, 1997;Hoffman, 2011) and among black men (Stanford et al, 1999;Greenlee et al, 2000). It has been also projected that PCa will be the commonest cancer in the UK by 2030 (Greenlee et al, 2000;Jeong et al, 2010).…”

Section: Introductionmentioning

confidence: 94%

DNA aptamer-based detection of prostate cancer

2015

View full text Add to dashboard Cite

The use of aptamers in biosensing has attracted considerable attention as an alternative to antibodies because of their unique properties such as long-term stability, cost-effectiveness and adjustability to various applications. Among cancers, the early diagnosis of prostate cancer (PCa) is one of the greatest concerns for ageing men worldwide. One of the most commonly used biomarkers for PCa is prostate-specific antigen (PSA), which can be found in elevated levels in patients with cancer. This review presents the gradual transition of research from antibody-based to aptamerbased biosensors, specifically for PSA. A brief description on aptamer-based biosensing for other PCa biomarkers is also presented. Special attention is given to electrochemical methods as analytical techniques for the development of simple, sensitive and cost-effective biosensors. The review also focuses on the different surface chemistries exploited for fabrication and their applications in clinical samples. The use of aptamers represents a promising tool for the development of point-ofcare biosensors for the early detection of prostate cancer. In view of the unmatched upper hand of aptamers, future prospects are also discussed, not only in the point-of-care format but also in other novel applications.

show abstract

Section: Introductionmentioning

confidence: 94%

DNA aptamer-based detection of prostate cancer

2015

View full text Add to dashboard Cite

show abstract

“…Hormonal manipulation also is being evaluated in patients with positive pelvic lymph nodes after radical prostatectomy [4]. A Medical Research Council trial also has shown that early hormonal manipulation has reduced complications and prolonged survival in metastatic prostate cancer [5]. Hormonal manipulation also is being evaluated in patients with biochemical recurrence after radical prostatectomy.…”

Section: Introductionmentioning

confidence: 98%

Preventing and treating the complications of hormone therapy

Kumar

Barqawi²,

Crawford³

2005

Curr Urol Rep

View full text Add to dashboard Cite

Hormonal manipulation in the form of androgen-deprivation therapy for prostate cancer was introduced by Huggins and Hodges in 1941 and resulted in a Nobel Prize in 1966. Hormonal therapy initially had been used in metastatic prostate cancer, but the indications have been expanded including failed local therapy, locally advanced prostate cancer, and neoadjuvant or adjuvant therapy in high-risk localized prostate cancer. In view of the magnitude of the problem of prostate cancer and relatively frequent use of hormonal manipulation, it is important for clinicians to be aware of common side effects, prevention, and treatment to improve quality of life and reduce morbidity and mortality in patients with prostate cancer. This review focuses on the common side effects of hormonal treatment such as osteoporosis, anemia, hot flashes, erectile dysfunction, muscle wasting, gynecomastia, decline in cognitive function, depression, increase in body fat and metabolic changes, and their prevention and treatment.

show abstract